€1.5m Price Tag Could Spell EU Success For BioMarin’s Hemophilia Gene Therapy

First Hemophilia A Gene Therapy Approval

 
• By Andrew McConaghie
  
Brisbane, CA, USA - Mar 1, 2020: The BioMarin logo seen at American biotechnology company BioMarin Pharmaceutical Inc.'s office in Brisbane, California.
The EU is vital for Roctavian's prospects, and the wider European and Middle East market two and half times larger than the US. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip